Ruti Aga and the Six-Year Arithmetic: How a Forged Prescription Turned a Knee Injection Into a Career Sentence

On the paper there was the name of a clinic that did not exist. The "doctor" who wrote the prescription was a family member with no medical registration, and when questioned he explained that he had used "an old prescription pad from a former workplace." When the Athletics Integrity Unit (AIU) contacted that workplace, the answer came back clean: no such pad had ever been issued from there. Three independent verification points, three identical verdicts. The smallest gap is usually where the story waits, and here the gap was the width of a prescription pad.

Ethiopian marathoner Ruti Aga has been banned for six years. The arithmetic is straightforward: two years for the presence violation, four years for tampering. Two and four, six. On the day that number surfaced, no timing sheet anywhere recorded a new mark — which is the quiet irony of this story. It is a piece of news with no performance in it, only process.

Aga's standing is known to anyone who tracks the marathon majors across a season. The 2026 Tokyo Marathon title is hers, along with three second-place finishes at World Marathon Majors. The 2:18:34 for second in Berlin 2026 comes from the public race record, not from the AIU statement. A 2:18–2:20 athlete with a major win, three major podiums and a name that inserts itself into any elite start list without being asked.

Now consider the economy this case was built inside. For East African marathoners, the weeks between majors are usually spent on the Asian label-race circuit — fewer races, larger appearance fees, lower risk. In March, Aga won a half marathon in China and was tested there. That is precisely the tier which, over the past few seasons, has become the AIU's highest-yield testing ground. The appearance-fee economy and the testing economy are colliding inside the same races.

I watch those label races from a UK desk at 2 a.m., and at that hour the distance between Tampere and Iten dissolves — but the scoreboard rarely says what the story says. I learned to read a scoreboard like a passport stamp: it tells you where someone came from, which category they entered under, and whose attention is on them.

The real technical argument starts here, and this is where the reporting slipped hardest.

Methylprednisolone is not an anabolic steroid. It is a glucocorticoid, class S9 on the WADA Prohibited List, and the defining condition of S9 is that it is prohibited in-competition only, and only by injection, oral or rectal routes. A therapeutic knee injection administered out of competition is entirely legal. It becomes a violation only if residues are present in a sample taken in-competition.

The entire case therefore rested not on steroid use but on route and timing. A road race's testing window opens at 23:59 the night before the race, which means an injection given days earlier with a properly observed washout is legally unremarkable. And if the arithmetic goes wrong, a legitimate defence still exists: medical necessity, documentation, timing.

Aga destroyed that defence herself.

The knee-injury explanation is mechanistically credible — intra-articular methylprednisolone for knee synovitis is standard sports-medicine practice in high-volume distance runners. That credibility was the thing that could have carried a defence. Once the document turned out to be forged, the credibility inverted. A genuine treatment is fought with real records; a fabricated prescription becomes proof that there were no real records to fight with.

My reading is that in this case the two years were the sentence for the substance and the four years were the sentence for the paper.

The two-year component is unremarkable. Under the WADA Code 2026, that is the standard period for a Specified Substance finding without proven intent — and it is worth noting that the panel declined the no-significant-fault mitigation that would have reduced it. The four-year component is the Code's standard tampering sanction, applied in full. The sum is mathematical evidence that the panel treated the substance charge as proven and the documentation as wholly culpable.

The tampering charge came not from a document but from an interview — from statements made under questioning. AIU interviews with Ethiopian athletes are routinely conducted across language and translation conditions, and that is where the legal argument now lives. Still, the CAS appeal window typically runs about 21 days from the reasoned decision, and document-based findings are hard to overturn.

The ban runs from 10 September, the same date the provisional suspension began. That is often read as relief. It is not relief. Provisional suspension time is credited against the ban; the athlete gains nothing in real terms.

Now the part that needs the most care.

Six years for a substance with no proven endurance benefit. That sentence will be used from both directions. One camp will cite it as proof of AIU rigour; another will cite it as proof of disproportionate enforcement against African road runners. Both have half the truth, and both walk past the actual point.

The actual point is that this is not a failure of anti-doping enforcement. It is a failure of medical governance.

The "doctor" was an unregistered family member. The clinic did not exist. The pad was attributed to a former workplace that explicitly disowned it. That is not a filing error. It is the signature of an athlete operating without a credentialed team physician. A properly managed athlete has two routes: hold or apply for a TUE, or observe the route-specific washout period. Neither appears to have happened — and when neither happens, the third route gets chosen, because it is the cheapest and the most dangerous.

One further media slippage deserves recording. Several reports called methylprednisolone a "prohibited steroid" and filed the case alongside anabolic-steroid matters. That is technically wrong, and the consequence is not confined to vocabulary. Calling a glucocorticoid a steroid presents a timing-and-documentation case as an outright cheating case, and that distinction will shape whether the next injured runner sits out a race after an injection or starts it.

What the story also omits is the scope of the sanction. The AIU statement does not say whether the March race result and its prize money are annulled. Standard practice is clear — the competition at which the sample was collected is disqualified automatically — but it is not written down. Nor do the 2026 Tokyo title and the three major podiums fall automatically, since the violation is anchored to a later date. I went looking for the year of that March race; the statement does not give it either. No Ethiopian federation statement appears anywhere. What a disciplinary release leaves out is often as informative as what it puts in.

Ethiopia's women's marathon depth is such that the removal of a 2:18 runner changes nothing in the national selection calculus. A six-year ban at 32 means a return at 38 — and at that age, with that record, the Ethiopian team door is functionally shut. The ban is six years on paper and a career on the ground.

The question that survives is not about Aga. It is about where an injured marathoner whose income runs on appearance fees goes when the knee gives out. If the answer is "a family member holding an old pad from a clinic," the next sanction will carry a different name, and we will read the same release again. Medical support that is not a structure becomes a risk — and the bill for that risk has now been paid by Ruti Aga.